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Studies evaluating bacterial prophylaxis of patients under 
high risk for the development of febrile neutropenia have 
been published since the 1980s.1-3 Initially, trimethoprim with 
sulfamethoxazole was used, but this is associated with an 
unacceptable risk of myelosuppression. Thus, fluoroquinolones 
became the treatment of choice worldwide, due to their good 
oral tolerability, broad antimicrobial spectrum, bactericidal 
activity, ability to preserve anaerobic gut microorganisms, and 
lack of myelotoxicity. Ciprofloxacin was initially used in this 
scenario, but the need to treat Streptococcus viridans led to a 
progressive trend to prescribing levofloxacin due to its better 
activity against this microorganism.4
Recent studies suggest that antibacterial prophylaxis with 
levofloxacin should be started when a neutropenia episode, 
secondary to chemotherapy, is expected. Decreasing rates of 
febrile neutropenic episodes and even all-cause mortality have 
been correlated with this approach.3,5,6 However, two aspects 
of this widely practiced procedure remain controversial and 
under discussion. First, it appears that the greatest benefit 
of antibiotic prophylaxis is restricted to patients who are 
expected to develop long and severe episodes of neutropenia 
(longer than seven days with neutrophils < 100 × 109 cells/L).7,8 
Second, increasing rates of fluoroquinolone resistance in this 
group of patients have been described in the medical literature, 
including in hematological services where this routine was 
adopted. The widespread use of antimicrobials in incorrectly 
selected patient populations and the rise in bacterial resistance 
to these drugs exemplify a well-known phenomenon in the 
field of antimicrobial therapy. Indeed, the massive use of 
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fluoroquinolones for prophylaxis and the emergence of 
bacterial resistance have already been noted in respiratory 
and genitourinary diseases.9-11  
Thus, efforts in implementing protocols in order to select 
patients at real risk for the development of long and severe 
febrile neutropenic episodes are urged. Patients submitted 
to hematopoietic stem cell transplants and those in the 
conditioning period of acute myeloid leukemia chemotherapy 
are at the highest risk of developing long and severe episodes of 
febrile neutropenia, and are therefore appropriate candidates 
to receive antimicrobial prophylaxis.8,9 This measure is able to 
decrease fluoroquinolone exposure in thousands of patients 
and potentially contribute to control bacterial resistance 
related to antimicrobial selective pressure.10,11 In this issue of 
the Revista Brasileira de Hematologia e Hemoterapia, Lopes et 
al. present a study on the use of prophylaxis with levofloxacin 
in a hematopoietic stem cell transplant unit.12
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